Landscape → Dermatology

Vitiligo Clinical Trial Landscape

Data updated: May 20, 2026

109 clinical trials tracked since 2008

Vitiligo is being studied across 109 clinical trials registered since 2008, with 46 programs currently active. The competitive pipeline includes 14 active Phase 3 trials, 23 active Phase 2 trials, and 8 active Phase 1 trials. Top industry sponsors include Incyte Corporation, Pfizer, Jiangsu HengRui Medicine Co., Ltd..

46 active

109 total (since 2008)

Phase 1 Active

16 total

Phase 2 Active

62 total

Phase 3 Active

31 total

Phase 4 Active

16 total

Top Industry Sponsors

Sorted by active Active Done Failed

Incyte Corporation 4 8 0

Pfizer 2 2 0

Jiangsu HengRui Medicine Co., Ltd. 2 0 0

AbbVie 1 1 0

Takeda 1 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06163326 ACTIVE NOT RECRUITING

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Pfizer n=394

NCT06113471 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Incyte Corporation n=450

NCT06072183 ACTIVE NOT RECRUITING

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

Pfizer n=1,571

NCT06113445 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Incyte Corporation n=467

NCT06548360 RECRUITING

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Incyte Corporation n=180

+ 26 more Phase 3 trials — see full database below

Vitiligo — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Incyte Corporation

Pfizer

Jiangsu HengRui Medicine Co., Ltd.

AbbVie

Takeda

Dren Bio

Novartis

Shanghai Longwood Biopharmaceuticals Co., Ltd.

Innovent Biologics (Suzhou) Co. Ltd.

Eli Lilly

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

51-200

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Incyte Corporation 4 8 0

Pfizer 2 2 0

Jiangsu HengRui Medicine Co., Ltd. 2 0 0

AbbVie 1 1 0

Takeda 1 0 0

Dren Bio 1 0 0

Novartis 1 0 0

Shanghai Longwood Biopharmaceuticals Co., Ltd. 1 0 0

Innovent Biologics (Suzhou) Co. Ltd. 1 0 0

Eli Lilly 1 0 0

Elixiron Immunotherapeutics (Hong Kong) Ltd. 1 0 0

Hudson Biotech 1 0 0

Teva Branded Pharmaceutical Products R&D LLC 1 0 0

CAGE Bio Inc. 1 0 0

Jiangsu vcare pharmaceutical technology co., LTD 1 0 0

NCT06163326 ACTIVE NOT RECRUITING

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Pfizer n=394

NCT07557693 NOT YET RECRUITING

Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo

Centre Hospitalier Universitaire de Nice n=5

NCT07509242 NOT YET RECRUITING

Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study

Yohanes Firmansyah, dr, MH, MM n=150

NCT06113471 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Incyte Corporation n=450

NCT06072183 ACTIVE NOT RECRUITING

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

Pfizer n=1,571

NCT06113445 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Incyte Corporation n=467

NCT06548360 RECRUITING

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Incyte Corporation n=180

NCT06804811 RECRUITING

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Incyte Corporation n=250

NCT06118411 ACTIVE NOT RECRUITING

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

AbbVie n=614

NCT07047612 RECRUITING

ICP-332 in Subjects With Non-segmental Vitiligo

Beijing InnoCare Pharma Tech Co., Ltd. n=603

NCT06109649 ACTIVE NOT RECRUITING

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Clinuvel, Inc. n=200

NCT06768840 RECRUITING

Vitiligo, New Treatment and Serum s100B

South Valley University n=50

NCT06719024 RECRUITING

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

Hospital Authority, Hong Kong n=20

NCT07595939 NOT YET RECRUITING

Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo

The Children's Hospital of Zhejiang University School of Medicine n=20

NCT05583526 COMPLETED

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

Pfizer n=607

NCT04057573 COMPLETED

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Incyte Corporation n=344

NCT04052425 COMPLETED

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Incyte Corporation n=330

NCT04530344 COMPLETED

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Incyte Corporation n=458

NCT04942860 COMPLETED

The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo

Nicolaus Copernicus University n=25

NCT05513924 COMPLETED

Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.

South Valley University n=40

NCT04774809 TERMINATED

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Reistone Biopharma Company Limited n=75

NCT02466997 COMPLETED

Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC

University Hospital, Bordeaux n=42

NCT02156427 COMPLETED

Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism

Laboratoires Genévrier n=38

NCT02191748 TERMINATED

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Rutgers, The State University of New Jersey n=22

NCT01822379 WITHDRAWN

Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo

Henry Ford Health System

NCT00631865 COMPLETED

Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin

Royan Institute n=300

NCT01419964 WITHDRAWN

Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Ache Laboratorios Farmaceuticos S.A.

NCT01841008 TERMINATED

Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control

Centre Hospitalier Universitaire de Nice n=35

NCT01629979 COMPLETED

Epidermal Cell Transplantation in Vitiligo Skin

Centre Hospitalier Universitaire de Nice n=23

NCT00830713 COMPLETED

Vitiligo Skin Transplantation

Henry Ford Health System n=40

NCT01087216 COMPLETED

Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo

Centre Hospitalier Universitaire de Nice n=20

NCT07108283 RECRUITING

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

Takeda

NCT07431177 RECRUITING

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Novartis Pharmaceuticals

NCT07548918 NOT YET RECRUITING

Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"

Sohag University

NCT07556471 NOT YET RECRUITING

Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo

Shanghai Longwood Biopharmaceuticals Co., Ltd.

NCT07533019 RECRUITING

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Eli Lilly and Company

NCT07519031 NOT YET RECRUITING

Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo

Xijing Hospital

NCT07223229 RECRUITING

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Elixiron Immunotherapeutics (Hong Kong) Ltd.

NCT07152626 RECRUITING

Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo

Centre Hospitalier Universitaire de Nice

NCT05342519 ACTIVE NOT RECRUITING

Daily Topical Rapamycin for Vitiligo

Medical University of South Carolina

NCT07437560 RECRUITING

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

Hudson Biotech

NCT07251595 RECRUITING

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

Jiangsu HengRui Medicine Co., Ltd.

NCT06790862 ACTIVE NOT RECRUITING

A Trial of SHR0302Base in Patients With Vitiligo

Jiangsu HengRui Medicine Co., Ltd.

NCT07172347 RECRUITING

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Jiangsu vcare pharmaceutical technology co., LTD

NCT07181187 ACTIVE NOT RECRUITING

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

Minghui Pharmaceutical (Hangzhou) Ltd

NCT07105254 RECRUITING

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Derm Texas, PLLC

NCT07016113 NOT YET RECRUITING

0.005% Latanoprost Gel for Nonsegmental Vitiligo

Universitas Padjadjaran

NCT06327321 ACTIVE NOT RECRUITING

Vitiligo Treatment by Targeting TYK2 Mediated Responses

Centre Hospitalier Universitaire de Nice

NCT06511739 RECRUITING

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

CSPC Ouyi Pharmaceutical Co., Ltd.

NCT04822584 COMPLETED

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

University Hospital, Bordeaux

NCT06493578 TERMINATED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Vyne Therapeutics Inc.

NCT04338581 COMPLETED

Evaluation of AMG 714 for Vitiligo

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02432534 COMPLETED

Atorvastatin in Active Vitiligo

Centre Hospitalier Universitaire de Nice

NCT03036995 COMPLETED

Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO

Centre Hospitalier Universitaire de Nice

NCT05750823 COMPLETED

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Incyte Corporation

NCT06113328 TERMINATED

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Merck Sharp & Dohme LLC

NCT04237103 COMPLETED

Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

University Hospital, Bordeaux

NCT04246372 COMPLETED

Tofacitinib for Immune Skin Conditions in Down Syndrome

University of Colorado, Denver

NCT04896385 COMPLETED

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

Incyte Corporation

NCT04487860 COMPLETED

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Ache Laboratorios Farmaceuticos S.A.

NCT05247489 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Incyte Corporation

NCT05872477 COMPLETED

Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

Centre Hospitalier Universitaire de Nice

NCT04927975 COMPLETED

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

AbbVie

NCT05607316 WITHDRAWN

Evaluating the Efficacy and Safety of Metformin in Vitiligo

University of Massachusetts, Worcester

NCT04811131 TERMINATED

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Arcutis Biotherapeutics, Inc.

NCT05298033 COMPLETED

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

University of Colorado, Denver

NCT04818346 COMPLETED

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Incyte Corporation

NCT04525157 COMPLETED

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

Clinuvel Pharmaceuticals Limited

NCT03099304 COMPLETED

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

Incyte Corporation

NCT03715829 COMPLETED

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Pfizer

NCT03468855 COMPLETED

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Aclaris Therapeutics, Inc.

NCT04103060 COMPLETED

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

Dermavant Sciences GmbH

NCT03247400 COMPLETED

The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo

Nicolaus Copernicus University

NCT02809976 COMPLETED

Topical Ruxolitinib for the Treatment of Vitiligo

Tufts Medical Center

NCT03123016 COMPLETED

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

Icahn School of Medicine at Mount Sinai

NCT01517893 COMPLETED

Clinical Trial of Simvastatin to Treat Generalized Vitiligo

John Harris

NCT01923142 TERMINATED

Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo

Centro Studi Gised

NCT01262547 TERMINATED

A New Micrografting Technique for Vitiligo

Massachusetts General Hospital

NCT01511965 COMPLETED

Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo

Centre Hospitalier Universitaire de Nice

NCT01701648 COMPLETED

Melanocyte Transplantation for Patients With Stable Vitiligo.

Clinica Universidad de Navarra, Universidad de Navarra

NCT01382589 COMPLETED

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

Clinuvel Pharmaceuticals Limited

NCT07353801 ACTIVE NOT RECRUITING

Oral Mini Pulse Dexamethasone in Pediatric Vitiligo

Cairo University

NCT07563049 ACTIVE NOT RECRUITING

Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.

Kasr El Aini Hospital

NCT07472816 NOT YET RECRUITING

The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.

Cairo University

NCT07352293 RECRUITING

The Value of Methotrexate in NCES for Stable Vitiligo

Cairo University

NCT05536856 RECRUITING

Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo

Al-Azhar University

NCT06991972 RECRUITING

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients

Khyber Teaching Hospital

NCT06593197 ENROLLING BY INVITATION

Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

Dow University of Health Sciences

NCT07368673 COMPLETED

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

Dow University of Health Sciences

NCT07174024 COMPLETED

A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.

Cairo University

NCT04775979 COMPLETED

Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo

Ain Shams University

NCT05676333 COMPLETED

Secukinumab in Active Non-segmental Vitiligo

University Hospital, Ghent

NCT01082393 COMPLETED

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

University Hospital, Ghent

NCT02458417 COMPLETED

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Netherlands Institute for Pigment Disorders

NCT01732965 COMPLETED

NB-UVB and PUVA Vitiligo Study

Henry Ford Health System

NCT01202513 WITHDRAWN

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Gian Sagar Medical College and Hospital

NCT01051687 COMPLETED

Botulinum Toxin Treatment for Localized Vitiligo

King Saud University

Full Vitiligo Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only